New Facility and Expanded Plans for the Mapping Cancer Markers Research Team

The Mapping Cancer Markers researchers recently moved to a new institute, but continues analyzing results, planning for expanded research, and creating new work units throughout the transition. Learn about their plans in this article.

The Mapping Cancer Markers project is currently processing data to identify biomarkers for ovarian cancer, one of the deadliest cancers for women.



The Mapping Cancer Markers (MCM) project continues to process data to identify biomarkers for ovarian cancer. We are also in the process of analyzing MCM results from the lung cancer dataset, and we are finalizing preparation of the new work units for sarcoma, a type of malignant tumor. We will devote more space in the next project update to this work. Below we provide details about an exciting new development in the team.

The Move

After more than 17 years at Ontario Cancer Institute (now Princess Margaret Cancer Centre), we got an opportunity to join Krembil Research Institute (KRI) to work on a more complex approach to chronic diseases, where we moved in mid-November. KRI is still part of the University Health Network in Toronto, but focuses also on arthritis, neuroscience, and vision. The research and translational clinical research interests focus not only on diagnosis and improved treatment, but importantly on prevention, which aligns with my group’s interest over the last few years.

Thus, MCM has not been negatively affected—the physical move was smooth, and our servers stayed in the original server rooms, reducing the risk of any hiccup for World Community Grid work units and results. We will not only continue, but will expand on our research.

New Computational Biology Platform

Importantly, we are in the finalizing stages of paperwork to embark on a newly-funded research by the Ontario Government: The Next Generation Signalling Biology Platform. This will provide us funds to create a software infrastructure for the comprehensive, integrative computational biology analyses workflows, in collaboration with translational research and clinical trials groups. Our partners are Princess Margaret Cancer Centre, Krembil Research Institute, University of Toronto, University of Montreal, BC Cancer Agency, Cancer Clinical Trials Group, Queen’s University, and European Bioinformatics Institute (IMEx Consortium). Besides focusing on cancer, this is our first large osteo-arthritis research project.

Thank you to everyone for your support, and we look forward to providing additional updates as our work progresses.

Related Articles